arrow
R

Rovina Ruslami

University of Indonesia
H指数:39
被引数:6,565

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis

成人结核性脑膜炎大剂量口服利福平的试验

2025-12-183
PRE
Inflammatory markers in the cerebrospinal fluid linked to mortality in tuberculous meningitis

脑脊液中的炎症标志物与结核性脑膜炎的死亡率相关

2025-07-160
OAAI
Inflammatory markers in the cerebrospinal fluid linked to mortality in tuberculous meningitis

脑脊液中与结核性脑膜炎死亡率相关的炎症标志物

2025-07-030
OAAI
Pre-treatment untargeted cerebrospinal fluid metabolomic profiling in tuberculous meningitis uncovers pathways associated with mortality

结核性脑膜炎患者脑脊液预处理的非靶向代谢组学分析揭示了与死亡率相关的通路

Med
IF11.8
2025-05-230
PREAI
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial

利福平敏感肺结核8周治疗方案的有效性和安全性(TRUNCATE-TB):一项多臂、多阶段、开放标签、随机对照试验的预设探索性分析

2025-05-220
OAAI
Analytical and clinical validation of a volumetric absorptive microsampling (VAMS) - Ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the analysis of Clofazimine in whole blood

体积吸收式微采样(VAMS)-超高效液相色谱-串联质谱(UPLC-MS/MS)方法在完整血液中氯法齐明分析的体外和临床验证

2025-03-011
PRE
High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial
2024-06-012
PRE
Sustainability and impact of an intervention to improve initiation of tuberculosis preventive treatment: results from a follow-up study of the ACT4 randomized trial
2024-05-010
OAAI
Impaired resolution of blood transcriptomes through tuberculosis treatment with diabetes comorbidity

通过结核病治疗与糖尿病合并症,血液转录组的分辨率受损

2023-08-302
OAAI
Clinical standards for the management of adverse effects during treatment for TB
2023-07-0114
OAAI
Tryptophan metabolism determines outcome in tuberculous meningitis: a targeted metabolomic analysis
2023-05-0911
OA
Treatment Strategy for Rifampin-Susceptible Tuberculosis
2023-03-0956
OA